2024 AAIC Poster
2024 AAIC Poster:
Sabirnetug (ACU193) Lowers CSF Levels of Synaptic Biomarkers in INTERCEPT-AD Phase 1 Study in Early AD
2024 ADPD Presentation
2024 ADPD Presentation:
Sabirnetug (ACU193) Lowers CSF Neurogranin & pTau181 Levels in INTERCEPT-AD Study in Early AD.
2024 AAN Presentation
2024 AAN Presentation:
A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.
2024 AAN Poster
2024 AAN Poster:
A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.
2022 CTAD Poster
2022 CTAD Poster:
Critical evaluation and comparison of biomarker values in commercial CSF with Lumipulse® to support assay development for clinical trials.
